Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positive (ER+) and lymph node negative (LN−) breast cancer. The RR is divided into low (0–17), intermediate (18–30), and high (31) to predict chemotherapy benefit. Our goal was to determine the association b...
Saved in:
Main Authors: | Matthew G. Hanna, Ira J. Bleiweiss, Anupma Nayak, Shabnam Jaffer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | International Journal of Breast Cancer |
Online Access: | http://dx.doi.org/10.1155/2017/1257078 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Utilization of Oncotype DX in an Inner City Population: Race or Place?
by: Amber A. Guth, et al.
Published: (2013-01-01) -
The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01) -
Performance evaluation of the Qiagen BK virus ASR on the NeuMoDx system
by: Amorce Lima, et al.
Published: (2025-02-01) -
Diagnostic Immunohistochemistry : theranostic and genomic application /
by: Dabbs, David J.
Published: (2014) -
Is immunohistochemistry a miracle tool?
by: Caridad Socorro Castro, et al.
Published: (2017-12-01)